PLYMOUTH MEETING, Pa., Oct. 31, 2025 /PRNewswire/ -- INOVIO $(INO)$, a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

The Compensation Committee of INOVIO's Board of Directors has approved the award of an option to purchase 3,000 shares of common stock with a grant date of October 31, 2025 (the "Grant Date"), to a newly hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $2.35, the closing price of INOVIO's common stock on October 31, 2025. The stock option will vest over a three-year period, with one-third of the shares vesting on each of the first, second and third anniversaries of the Grant Date. The vesting of the stock option will be subject to the employee's continued employment with INOVIO on the applicable vesting dates. This award is subject to the terms and conditions of a stock option agreement under the Inducement Plan.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts

Media: Jennie Willson, (267) 429-8567, communications@inovio.com

Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-reports-inducement-grant-under-inducement-plan-302601463.html

SOURCE INOVIO Pharmaceuticals, Inc.

(END) Dow Jones Newswires

October 31, 2025 16:53 ET (20:53 GMT)